MY162741A - Improved cancer therapy based on tumor associated antigens derived from cyclin D1 - Google Patents
Improved cancer therapy based on tumor associated antigens derived from cyclin D1Info
- Publication number
- MY162741A MY162741A MYPI2012700611A MYPI2012700611A MY162741A MY 162741 A MY162741 A MY 162741A MY PI2012700611 A MYPI2012700611 A MY PI2012700611A MY PI2012700611 A MYPI2012700611 A MY PI2012700611A MY 162741 A MY162741 A MY 162741A
- Authority
- MY
- Malaysia
- Prior art keywords
- cyclin
- cancer therapy
- associated antigens
- tumor associated
- therapy based
- Prior art date
Links
- 102000006311 Cyclin D1 Human genes 0.000 title abstract 2
- 108010058546 Cyclin D1 Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/001149—Cell cycle regulated proteins, e.g. cyclin, CDC, CDK or INK-CCR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35073110P | 2010-06-02 | 2010-06-02 | |
| GB201009222A GB201009222D0 (en) | 2010-06-02 | 2010-06-02 | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY162741A true MY162741A (en) | 2017-07-15 |
Family
ID=42471037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012700611A MY162741A (en) | 2010-06-02 | 2011-06-01 | Improved cancer therapy based on tumor associated antigens derived from cyclin D1 |
Country Status (17)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN103848891B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Ccnd1自身抗体识别的抗原多肽 |
| US10206985B2 (en) * | 2013-02-05 | 2019-02-19 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for mucosal administration |
| CA2841016A1 (en) * | 2013-02-05 | 2014-08-05 | Nitto Denko Corporation | Wt1 peptide cancer vaccine composition for transdermal administration |
| ES3009756T3 (en) | 2013-08-05 | 2025-03-31 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer including nsclc |
| TWI777196B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（五） |
| CN104017051B (zh) * | 2014-06-23 | 2016-08-17 | 深圳市华中生物药械有限公司 | 一种Cyclin D 蛋白抑制剂多肽及其应用 |
| CR20200526A (es) | 2015-06-19 | 2020-12-23 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA Y MÉTODOS PARA CREAR SOPORTES PARA EL USO CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2018-0040) |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| HK1254866A1 (zh) | 2015-06-25 | 2019-07-26 | Immatics Biotechnologies Gmbh | 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物 |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MA51531A (fr) * | 2015-07-06 | 2020-11-11 | Immatics Biotechnologies Gmbh | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201602918D0 (en) * | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| CN114028549A (zh) | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN112553336B (zh) * | 2020-12-17 | 2023-07-21 | 兰州大学 | Snp在乳腺癌化疗耐药性检测领域的应用及其检测试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2005035714A2 (en) | 2003-08-26 | 2005-04-21 | Board Of Regents, The University Of Texas System | Vaccines for cancer, autoimmune disease and infections |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| PL1642905T3 (pl) | 2004-10-02 | 2009-04-30 | Immatics Biotechnologies Gmbh | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy |
| SI1806359T1 (sl) * | 2005-09-05 | 2010-06-30 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II |
| ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| UA103882C2 (uk) | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
| EP3085707B1 (en) * | 2007-11-01 | 2019-02-27 | Mayo Foundation for Medical Education and Research | Hla-dr binding peptides and their uses |
| ES2532896T5 (es) * | 2008-05-14 | 2018-03-20 | Immatics Biotechnologies Gmbh | Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan |
| JP5883653B2 (ja) * | 2009-03-10 | 2016-03-15 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 抗原提示細胞ターゲティング抗ウイルスワクチン |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
-
2010
- 2010-06-02 GB GB201009222A patent/GB201009222D0/en not_active Ceased
-
2011
- 2011-06-01 JP JP2013512926A patent/JP2013536157A/ja active Pending
- 2011-06-01 UA UAA201210089A patent/UA110473C2/uk unknown
- 2011-06-01 MY MYPI2012700611A patent/MY162741A/en unknown
- 2011-06-01 CN CN2011800266565A patent/CN102971003A/zh active Pending
- 2011-06-01 SG SG2012065918A patent/SG185353A1/en unknown
- 2011-06-01 EP EP11722825.4A patent/EP2575850A1/en not_active Withdrawn
- 2011-06-01 US US13/643,043 patent/US9023803B2/en active Active
- 2011-06-01 NZ NZ60167711A patent/NZ601677A/en not_active IP Right Cessation
- 2011-06-01 MX MX2012013998A patent/MX2012013998A/es active IP Right Grant
- 2011-06-01 EA EA201291195A patent/EA201291195A1/ru unknown
- 2011-06-01 CA CA2793601A patent/CA2793601A1/en not_active Abandoned
- 2011-06-01 US US13/150,785 patent/US9056069B2/en active Active
- 2011-06-01 PH PH1/2012/501898A patent/PH12012501898A1/en unknown
- 2011-06-01 KR KR1020127034291A patent/KR20130089175A/ko not_active Ceased
- 2011-06-01 AU AU2011260277A patent/AU2011260277B2/en not_active Ceased
- 2011-06-01 WO PCT/EP2011/059121 patent/WO2011151403A1/en not_active Ceased
- 2011-06-01 BR BR112012030479A patent/BR112012030479A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US9023803B2 (en) | 2015-05-05 |
| NZ601677A (en) | 2015-01-30 |
| JP2013536157A (ja) | 2013-09-19 |
| AU2011260277A1 (en) | 2012-08-30 |
| AU2011260277B2 (en) | 2015-01-15 |
| WO2011151403A1 (en) | 2011-12-08 |
| MX2012013998A (es) | 2013-01-28 |
| KR20130089175A (ko) | 2013-08-09 |
| BR112012030479A2 (pt) | 2017-01-24 |
| GB201009222D0 (en) | 2010-07-21 |
| EA201291195A1 (ru) | 2014-06-30 |
| US9056069B2 (en) | 2015-06-16 |
| UA110473C2 (uk) | 2016-01-12 |
| PH12012501898A1 (en) | 2019-07-10 |
| US20130177525A1 (en) | 2013-07-11 |
| SG185353A1 (en) | 2012-12-28 |
| CA2793601A1 (en) | 2011-12-08 |
| EP2575850A1 (en) | 2013-04-10 |
| US20120027684A1 (en) | 2012-02-02 |
| CN102971003A (zh) | 2013-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501898A1 (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 | |
| IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
| IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
| MX2019001920A (es) | Arn la terapia contra el cancer. | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| MX2022001105A (es) | Anticuerpos anti tigit. | |
| EP4364796A3 (en) | Use of linagliptin in cardio- and renoprotective antidiabetic therapy | |
| PH12012502044A1 (en) | Robo1-fc fusion protein and use thereof for treating tumours | |
| MX2018010483A (es) | Inmunogenos para vacunacion contra vih. | |
| SI2852408T1 (sl) | Kombinacijska terapija, ki vključuje protitelesa proti claudin 18.2 za zdravljenje raka | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| MX2013003859A (es) | Polimorfos de picropodofilina b o c para su uso en la terapia del cancer. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| PH12014500973A1 (en) | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | |
| WO2014009245A3 (en) | Novel drug target indentification methods | |
| HK1182922A (en) | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |